Engage Bio
Potent, durable, and redosable non-viral genetic medicines
San Francisco
10 employees
Synthetic Biology
Seed · $4M
About Engage Bio
Engage Bio has developed Tethosomes, a new class of non-viral DNA which finally unleashes potent, durable, redosable, and scalable genetic medicine.
In 2026 Engage was acquired by Eli Lilly.
Company details
Team Size10
LocationSan Francisco
IndustrySynthetic Biology
Funding
Total raised
$4M
Last stage
Seed
Investors
SSciFounders
CCal Innovation Fund
CCystic Fibrosis Foundation
Founders
WO
Will Olsen
Co-Founder & CEO of Engage Bio
KK
Kathryn Kwant
Co-founder of Engage Bio; previously advanced clinical development programs at Harpoon Therapeutics.
What happens next.
No applications, no recruiter spam. Just the intro.
01
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
02
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
03
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.